35% of doctors are more afraid of the hype around coronavirus than of the epidemic itself, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors.

In 2019, Russia imported 132 bln RUB worth of APIs (customs clearance prices, VAT included), which is monetary terms (rubles) 36.3% higher than that in 2018. The import volume in physical terms amounted to 13.2 thousand tons, with the dynamics of +10.2%. The average prices have risen from 8.1 thousand RUB / 1 kg to 10 thousand RUB / 1 kg by the end of 2019.

In 2019, Russia imported 37 bln RUB worth of veterinary drugs (customs clearance, VAT included), which is in monetary terms (rubles) 39.7% higher than that in 2018. The dynamics of the import of feed supplements have turned out negative for the first time since 2010 (-5.3%), with the total volume of 36.4 bln RUB. As for veterinary APIs, the import volume is 3.2 bln RUB, with the dynamics of +66%.

In 2019, Russia imported 759.2 bln RUB worth of pharmaceutical drugs (customs clearance prices, VAT included). The import volume together with the import dynamics in rubles (+42.8%) hit historic highs. The dynamics of the in-bulk import, while not record-worthy, were also rather high (+22.7%). However, the total in-bulk import volume did hit a historic high with 129.8 bln RUB.

43% of doctors prefer to prescribe original drugs, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors.

Despite the relatively good results of last year, the overall profitability in the supply chain leaves much to be desired. First of all, this concerns the retail segment of the market, since the growth in 2019 is significantly lower than inflation, without any positive outlook, apart from the coronavirus, which might somewhat stabilize the situation. In addition, the Russian pharmaceutical retail market decided to follow the “big retail” and enter the era of global transformation together with the online segment.

The coronavirus epidemic in China has definitely become one of the central issues of the early 2020. It is difficult to predict how the situation will evolve, and what consequences the healthcare system and the economy will have to face. However, the aspect of a certain cultural phenomenon in our country, formed by COVID-2019, is hard to ignore.

In 2019, Russia manufactured 425.3 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 26.6% higher than that in 2018. The results are the highest since the financial crisis between 2015 and 2016. The dynamics in physical terms are +7.4% in units and +6.4% in minimum dosage units (MDU), with 4.5 bln units of ready-made pharmaceuticals, or 75 bln MDUs.

The volume of Russian households’ purchases of veterinary drugs amounted to 20.6 bln RUB (retail prices, VAT included) in 2019. The volume of purchases in physical terms is over 110 mln units (or over 199 mln MDUs), including veterinary products sold in single-unit packages.

Despite a flurry of criticism of the activities of the former members of the Ministry of Health, only 5% of doctors believe that the new Government of the Russian Federation will make fundamental changes to the key issues of the organization of the health system, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Most respondents (43%) are sure that not only personnel changes, but also a revision of the decision-making and responsibility system is necessary to change the current situation.